Reinterpreting the matched-sibling relapse penalty in ATG-based allogeneic transplantation for myelodysplastic neoplasms: a question of dose, not donor Authors: Naif I AlJohani Published: 2026 ABSTRACT AbstractPark and colleagues recently reported, in a single-centre Korean cohort of 391 adult patients with myelodysplastic neoplasms (MDS) receiving fludarabine–busulfan conditioning and antithymocyte globulin (ATG)-based prophylaxis, that matched sibling donor (MSD) recipients experienced a substantially higher 5-year cumulative incidence of relapse (34.3%) than recipients of unrelated (UD; 16.4%) or haploidentical (HID; 16.8%) donors, with reduced acute and chronic graft-versus-host disease (GVHD) in the MSD arm. The authors conclude that under ATG-based prophylaxis, MSD may no longer be the optimal donor choice in MDS. We respectfully argue that this conclusion is constrained by two structural features of the cohort. First, ATG dose is severely confounded with donor type: 61.3% of MSD recipients received 10 mg/kg ATG versus 0% of HID recipients, a dose pattern that inverts standard clinical practice and overlaps a range in which independent evidence indicates impaired disease control without offsetting GVHD benefit. Second, the GVHD- non-relapse mortality pattern in the cohort is more consistent with a cumulative immunosuppression-intensity hypothesis than with a primary donor-source effect. We propose that the most clinically actionable inference is to re-examine ATG dosing in MSD transplants for MDS, rather than to displace MSD as a preferred donor.Keywords: Myelodysplastic neoplasms, Allogeneic hematopoietic stem cell transplantation, Antithymocyte globulin, Donor selection, Graft-versus-leukemia, Confounding by indication To the Editor: Park and colleagues report a thought-provoking single-centre analysis of 391 adult patients with myelodysplastic neoplasms (MDS) who underwent allogeneic hematopoietic cell transplantation (allo-HCT) with fludarabine–busulfan conditioning and Antithymocyte globulin (ATG) between 2009 and 2019 [1]. They observe a substantially higher 5-year cumulative incidence of relapse in matched sibling donor (MSD) recipients (34.3%) than in unrelated donor (UD; 16.4%) or haploidentical donor (HID; 16.8%) recipients (p < 0.001), with reduced acute and chronic graft-versus-host disease (GVHD) in the MSD arm. The authors conclude that under ATG-based prophylaxis, MSD may no longer represent the optimal donor choice in MDS. Their dataset is valuable, and the long-term follow-up of 108 months for survivors is unusual and welcome. We respectfully suggest, however, that the conclusions are constrained by structural features of the cohort that warrant emphasis before clinicians outside the institution adopt this framework. The comparison is at least as much about ATG dose as about donor type, and the dose pattern itself is non-physiologic The distribution of ATG exposure across donor groups (Table 1 of the report) is severely imbalanced (summarized here in Table 1). Sixty-one per cent of MSD recipients received 10 mg/kg ATG, compared with 0% of HID recipients; conversely, 56% of HID recipients received ≤ 5 mg/kg, compared with only 6.5% of MSD recipients [1]. This is not a modest covariate imbalance-it represents substantial confounding between donor type and in-vivo T-cell depletion intensity. Critically, the dose pattern in this cohort is also clinically counterintuitive. ATG is conventionally dosed higher in unrelated and haploidentical donor settings to compensate for greater HLA disparity and elevated GVHD risk, and lower in matched sibling donor settings where baseline GVHD risk is lower [2]. Park et al. invert this standard pattern, allocating the highest cumulative ATG exposure to the donor type with the lowest expected GVHD risk. This is consequential because available evidence indicates that ATG doses below 6 mg/kg are sufficient for GVHD prophylaxis in MSD transplantation, while higher cumulative doses impair disease control without offsetting benefit on GVHD: Devillier and colleagues, in an EBMT acute leukemia working party analysis of 234 patients undergoing RIC-MSD transplantation for AML in first complete remission, found that ATG ≥ 6 mg/kg significantly increased relapse incidence (52% vs. 26%) without reducing acute or chronic GVHD relative to < 6 mg/kg [3]. Independent prospective and retrospective data from MSD cohorts have replicated the finding that lower total ATG doses (≤ 5 mg/kg) provide effective GVHD prophylaxis without compromising disease control [4, 5]; a recent systematic review and meta-analysis of 22 dose-comparison studies further found that ATG doses ≥ 7 mg/kg were associated with a significantly higher relapse rate than lower doses (relative risk 1.34, 95% CI 1.07–1.67), with a number needed to harm of 7.7 for one-year relapse [6]. The plausible interpretation of Park et al.’s headline finding is therefore that the MSD arm was systematically over-dosed with ATG by contemporary standards, and the relapse penalty observed in MSD recipients reflects this over-dosing rather than a property of the matched sibling donor source. If MSD recipients had received ATG at the doses given to the HID arm, their relapse outcomes might well have approximated those of the alternative-donor groups. Multivariable adjustment for ATG dose cannot reliably separate the two effects when key strata are sparse or absent (≤ 5 mg/kg MSD subgroup, n = 10; 10 mg/kg HID subgroup, n = 0). The stratified subgroup analysis presented by the authors is undermined by the same sparsity. A reframing of this signal as one primarily reflecting cumulative T-cell depletion intensity, rather than donor source per se, would substantially change clinical implications: it would argue not for preferring alternative donors, but for re-examining ATG dosing in MSD transplants-a position the authors themselves gesture toward in their concluding paragraph. Table 1Joint distribution of donor type, ATG dose, TBI exposure, and donor age in the cohort reported by Park et al. [1]Treatment variableMSD (n = 155)UD (n = 134)HID (n = 102)p-valueATG ≤ 5.0 mg/kg, n (%)10 (6.5)15 (11.2)57 (55.9)< 0.001ATG 7.5 mg/kg, n (%)50 (32.3)47 (35.1)45 (44.1)-ATG 10 mg/kg, n (%)95 (61.3)72 (53.7)0 (0.0)-Any TBI exposure, n (%)31 (20.0)34 (25.4)102 (100.0)< 0.001Donor age (median, years)482935< 0.0015-year CIR (%)34.316.416.8< 0.001CIR cumulative incidence of relapse, HID haploidentical donor, MSD matched sibling donor, TBI total body irradiation, UD unrelated donor Joint distribution of donor type, ATG dose, TBI exposure, and donor age in the cohort reported by Park et al. [1] CIR cumulative incidence of relapse, HID haploidentical donor, MSD matched sibling donor, TBI total body irradiation, UD unrelated donor The authors’ own GVHD and NRM data support an over-immunosuppression interpretation. If reduced GVHD in MSD recipients translates into reduced GVL and therefore higher relapse, the converse should also hold: the donor group with the highest GVHD burden should pay the steepest non-relapse mortality (NRM) price. The reported data do not show this. HID recipients had the highest cumulative incidence of grade II–IV acute GVHD (HR 2.567, 95% CI 1.573–4.195 vs. MSD) and the highest moderate-to-severe chronic GVHD (HR 2.230, 95% CI 1.341–3.710) [1], yet 5-year NRM in the HID group (20.6%) was not significantly different from MSD (15.5%; multivariable HR 1.489, 95% CI 0.869–2.552, p = 0.150). HID recipients therefore appear to convert their additional GVHD burden into preserved GVL activity-and lower relapse-without a commensurate NRM penalty. MSD recipients, conversely, exhibit reduced GVHD without proportionate GVL benefit, suggesting that in vivo T-cell depletion in MSD transplants is approaching the upper margin of useful immunosuppression and entering a range where GVHD prevention is achieved at the cost of disease control. This pattern is internally consistent with the cumulative-immunosuppression-intensity hypothesis and difficult to reconcile with a model in which donor source itself is the primary determinant of relapse. We thank Park and colleagues for an analysis that highlights an underrecognized tension in donor selection for MDS: the cost of in-vivo T-cell depletion in graft-versus-leukemia activity. The data are most consistent, in our view, with a cumulative immunosuppression-intensity hypothesis in which excess ATG exposure in MSD transplants attenuates GVL more than in other donor settings [7–10]. The clinically actionable inference is not that MSD has been displaced as the preferred donor in MDS, but that ATG dosing in MSD transplants merits prospective re-evaluation, and that conclusions from heavily protocol-stratified retrospective cohorts should be tempered before being generalized across centers with different conditioning, prophylaxis, and supportive-care platforms. Author contributions NIA conceived, drafted, and approved the final manuscript. Funding No funding was received to assist with the preparation of this manuscript. Competing interests The author has no relevant financial or non-financial interests to disclose. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval Not applicable. This Matters Arising piece is a post-publication scientific commentary and does not involve human or animal participants, data, or biological material. Consent to participate Not applicable. Consent to publish Not applicable. Competing interests The author has no relevant financial or non-financial interests to disclose. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.